The Journal of Bone and Joint Surgery (American). 2005;87:293-301.
doi:10.2106/JBJS.D.01772
© 2005 The Journal of Bone and Joint Surgery, Inc.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the activities for this article:
 Adult Hip Reconstruction Test 12: Spring 2005
Adult Knee Reconstruction Test 8: Spring 2005
Right arrow [Supplementary Material]
Right arrow Letters to the Editor: Submit a response
Right arrow Letters to the Editor: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhandari, M.
Right arrow Articles by Einhorn, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhandari, M.
Right arrow Articles by Einhorn, T. A.
Related Collections
Right arrow Adult Hip
Right arrow Adult Knee
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Facebook   Add to Technorati   Add to Twitter  
What's this?

Effect of Bisphosphonates on Periprosthetic Bone Mineral Density After Total Joint Arthroplasty

A Meta-Analysis

Mohit Bhandari, MD, MSc, FRCSC1, Sohail Bajammal, MD1, Gordon H. Guyatt, MD, MSc1, Lauren Griffith, MSc1, Jason W. Busse, DC, MSc1, Holger Schünemann, MD, PhD1 and Thomas A. Einhorn, MD2

1 Department of Clinical Epidemiology and Biostatistics, McMaster University Health Sciences Center, Room 2C9, 1200 Main Street West, Hamilton, ON L8N 3Z5, Canada. E-mail address for M. Bhandari: bhandam{at}mcmaster.ca
2 Department of Orthopaedic Surgery, Boston University Medical Center, 720 Harrison Avenue, Suite 808, Boston, MA 02118

Investigation performed at the Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada, and the Department of Orthopaedic Surgery, Boston University Medical Center, Boston, Massachusetts

In support of their research or preparation of this manuscript, one or more of the authors received grants or outside funding from a Canadian Institutes of Health Research Fellowship Award. In addition, one or more of the authors received payments or other benefits or a commitment or agreement to provide such benefits from commercial entities (Merck and Novartis). No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, educational institution, or other charitable or nonprofit organization with which the authors are affiliated or associated.

Background: Periprosthetic bone loss following total joint arthroplasty may threaten the survival of the implant. Bisphosphonates are effective in reducing bone loss in conditions associated with accelerated bone turnover. To determine the current understanding of the effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty, we conducted computerized searches for randomized controlled trials evaluating the use of bisphosphonates in patients treated with primary total joint arthroplasty.

Methods: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, the web site of the United Kingdom National Research Register, and the archives of the American Academy of Orthopaedic Surgeons annual meetings (1989 through 2003), and we conducted hand searches of the bibliographies of relevant articles. We assessed methodological quality and abstracted relevant data. When necessary, we contacted authors to provide additional information.

Results: Of 386 citations that were initially identified, six (five complete papers and one abstract), which included a total of 290 patients, met our inclusion criteria. Those papers showed that significantly less periprosthetic bone loss had occurred in the bisphosphonate-treated patients than in the control patients at three months (152 patients; weighted mean difference, 3.3%; 95% confidence interval, 1.9% to 4.7%; p < 0.01), six months (248 patients; weighted mean difference, 4.5%; 95% confidence interval, 1.6% to 7.4%; p < 0.001), and twelve months (197 patients; weighted mean difference, 4.2%; 95% confidence interval, 1.5% to 6.9%; p = 0.03). Bisphosphonates appeared to have a larger effect on bone loss following arthroplasties with cement than on bone loss following arthroplasties without cement (difference, 0.1%, 5%, and 5.4% at three, six, and twelve months; significant difference [p < 0.001] at one year only) and a larger effect on bone loss following total knee arthroplasties than on bone loss following total hip arthroplasties (difference, 4.1%, 11.5%, and 7.1% at three, six, and twelve months; significant difference [p < 0.001] at six months only). None of the studies related the effects of bisphosphonates on bone mineral density to clinically relevant outcomes.

Conclusions: A meta-analysis of six randomized controlled trials suggested that bisphosphonates have a beneficial effect with regard to maintaining more periprosthetic bone mineral density than that in controls. However, the limitations of the available studies and the lack of analyses of clinically relevant outcomes (functional outcomes, revision rates, and quality of life) necessitate the planning and conduct of a sufficiently sized, methodologically sound study with clinically relevant end points. Until this has been done, the current evidence regarding the beneficial effects of bisphosphonates on periprosthetic bone after total joint arthroplasty should be interpreted with caution.

Level of Evidence: Therapeutic Level I. See Instructions to Authors for a complete description of levels of evidence.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Facebook Facebook   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JBJSHome page
G. Friedl, R. Radl, C. Stihsen, P. Rehak, R. Aigner, and R. Windhager
The Effect of a Single Infusion of Zoledronic Acid on Early Implant Migration in Total Hip Arthroplasty. A Randomized, Double-Blind, Controlled Trial
J. Bone Joint Surg. Am., February 1, 2009; 91(2): 274 - 281.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
S. J. Suratwala, S. K. Cho, J. J. van Raalte, S. H. Park, S. W. Seo, S.-S. Chang, T. R. Gardner, and F. Y.-I. Lee
Enhancement of Periprosthetic Bone Quality with Topical Hydroxyapatite-Bisphosphonate Composite
J. Bone Joint Surg. Am., October 1, 2008; 90(10): 2189 - 2196.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
L. Gehrig, J. Lane, and M. I. O'Connor
Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons
J. Bone Joint Surg. Am., June 1, 2008; 90(6): 1362 - 1374.
[Full Text] [PDF]

Home page
 JBJSHome page
F. A. Matsen III, J. Clinton, J. Lynch, A. Bertelsen, and M. L. Richardson
Glenoid Component Failure in Total Shoulder Arthroplasty
J. Bone Joint Surg. Am., April 1, 2008; 90(4): 885 - 896.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
M. H. Huo and N. F. Gilbert
What's New in Hip Arthroplasty
J. Bone Joint Surg. Am., September 1, 2005; 87(9): 2133 - 2146.
[Full Text] [PDF]

Letters to the Editor:

Read all Letters to the Editor

Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty.
Nitin. R Shetty, et al.
JBJS Online, 31 May 2005 [Full text]
Dr. Bhandari and colleagues respond to Dr Shetty et al
Mohit Bhandari, M.D., et al.
JBJS Online, 31 May 2005 [Full text]